ClinicalTrialsFinder
RecruitingPhase 1NCT07338838

To Evaluate the Tolerability and Pharmacokinetics of TQB3142 for Injection in Patients With Advanced Malignant Tumors

A Phase I Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of TQB3142 for Injection in Patients With Advanced Malignant Tumors

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Enrollment

66 participants

Start Date

Feb 26, 2026

Study Type

INTERVENTIONAL

Conditions

Advanced Malignant Tumors

Summary

To explore the safety, tolerability and pharmacokinetics of TQB3142 for injection in subjects with advanced malignant tumors

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called TQB3142 injection for people with advanced malignant tumors. The study is currently recruiting participants at 5 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTQB3142 injection

TQB3142 for injection is a B-cell lymphoma-extra large inhibitor.

Locations(5)

Guangzhou First Municipal People's Hospital

Guangzhou, Guangdong, China

Henan Cancer Hospital

Zhengzhou, Henan, China

Sichuan Cancer Hospital

Chengdu, Sichuan, China

The Affiliated Hospital of Southwest Medical University

Luzhou, Sichuan, China

The First Affiliated Hospital , College of Medicine, Zhejiang University

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07338838

Related Trials

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

NCT067647718 locations

A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors

NCT070380051 location

First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors

NCT068776501 location

A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors

NCT070164901 location

A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors

NCT0704375119 locations